Rouprêt M, Seisen T, Birtle AJ et al (2023) European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur Urol 84:49–64

Article  PubMed  Google Scholar 

Kolawa A, D’Souza A, Tulpule V (2023) Overview, diagnosis, and perioperative systemic therapy of upper tract urothelial carcinoma. Cancers. https://doi.org/10.3390/cancers15194813

Article  PubMed  PubMed Central  Google Scholar 

Tufano A, Cordua N, Nardone V et al (2022) Prognostic significance of organ-specific metastases in patients with metastatic upper tract urothelial carcinoma. J Clin Med. https://doi.org/10.3390/jcm11185310

Article  PubMed  PubMed Central  Google Scholar 

Fradet Y, Bellmunt J, Vaughn DJ et al (2019) Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol Off J Eur Soc Med Oncol 30:970–976

Article  CAS  Google Scholar 

Balar AV, Castellano DE, Grivas P et al (2023) Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol Off J Eur Soc Med Oncol 34:289–299

Article  CAS  Google Scholar 

Goto Y, Tanaka S, Maruo M et al (2022) Pathological complete response of plasmacytoid variant bladder cancer to pembrolizumab following genomic analysis. IJU case reports 5:304–307

Article  PubMed  PubMed Central  Google Scholar 

Miyama Y, Kanao K, Uranishi K et al (2023) Complete response to pembrolizumab in a patient with recurrent and metastatic urothelial bladder carcinoma reflecting coexisting sarcomatoid subtype and glandular differentiation: a case report. Int Can Conf J 12:24–30

Article  Google Scholar 

Lemke E, Sahasrabudhe D, Guancial E et al (2020) The role of metastasectomy in urothelial carcinoma: where are we in 2020? Clin Genitourin Can 18:e478–e483

Article  Google Scholar 

Piontkowski AJ, Corsi N, Morisetty S et al (2022) Benefit of lymph node dissection in cN+ patients in the treatment of upper tract urothelial carcinoma: analysis of NCDB registry. Urol Oncol 40:409.e409-409.e417

Article  Google Scholar 

Shigeta K, Matsumoto K, Ogihara K et al (2022) Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study. Urol Oncol 40:105.e119-105.e126

Article  Google Scholar 

Ito K, Kita Y, Yokomizo A et al (2023) Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study. Cancer Med 12:2325–2332

Article  PubMed  CAS  Google Scholar 

Voskuilen CS, Schweitzer D, Jensen JB et al (2020) Diagnostic Value of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography for lymph node staging in patients with upper tract urothelial carcinoma. Eur Urol Oncol 3:73–79

Article  PubMed  Google Scholar 

Suzuki K, Terakawa T, Furukawa J et al (2020) Nivolumab-induced adrenal insufficiency in patients with renal cell carcinoma. J Immunother. https://doi.org/10.1097/CJI.0000000000000299

Article  PubMed  Google Scholar 

Xiang J, Liu X, Hao Y et al (2023) Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced adrenal insufficiency. Transl Oncol 38:101787

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bhatlapenumarthi V, Patwari A, Harb AJ (2021) Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience. J Cancer Res Clin Oncol 147:2789–2800

Article  PubMed  CAS  Google Scholar